Univ.-Prof. Dr. med. Angela Krackhardt

Publications:

1. Bräunlein E, Lupoli G, Abualrous ET, de Andrade Krätzig N, Gosmann, D, Füchsl, F, Wiesbrock L, Lange S, Engleitner T, Lan H, Audehm S, Effenberger M, Boxberg M, Steiger K, Chang Y, Yu,K, Atay C, Bassermann F, Weichert W, Busch DH, Rad R, Freund C, Antes A, **Krackhardt AM**: Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma, Journal of Immuntherapy of Cancer in press.

2. Bräunlein E and **Krackhardt AM**: Identifizierung von Neoantigenen für immuntherapeutische Ansätze, Der Onkologe, in press

3. Wilhelm M, Zolg DP, Graber M, Gessulat M, Schmidt T, Schnatbaum K, Schwencke-Westphal C, Seifert P, de Andrade Krätzig N, Zerweck J, Knaute T, Bräunlein E, Samaras P, Lautenbacher L, Klaeger S, Wenschuh H, Rad R, Delanghe B, Huhmer A, Carr SA, Clauser KR, **Krackhardt AM**, Reimer U, Kuster B: Deep learning boosts immunopeptidomics one mass spectrum at a time; Nature Communications 2021, 12(1):3346. doi: 10.1038/s41467-021-23713-9.

4. Krabbe T, Marek J, Groll T, Steiger K, Schmid RM, **Krackhardt AM**, Altomonte J: Adoptive cell therapy is complemented by oncolytic virotherapy with fusogenic VSV-NDV in combination treatment of murine melanoma. Cancers 2021, https://doi.org/10.3390/cancers13051044.

5. Robu S, Richter A, Gosmann D, Seidl C, Leung D, Hayes W, Cohen D, Morin P, Donnelly DJ, Lipovšek D, Bonacorsi SJ, Smith A, Steiger K, Aulehner C, **Krackhardt AM**, Weber WA: Synthesis and Preclinical evaluation of 68Ga-labeled Adnectin, 68Ga-BMS-986192 as a PET agent for Imaging PD-L1 expression. J Nucl Med 2021, doi: 10.2967/jnumed.120.258384.

6. Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Amon L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis CA, Conway J, He MX, Elmarakeby H, Dietlein F, Miao D, Tracy A, Gogas H, Goldinger SM, Utikal J, Blank CU, Rauschenberg R, von Bubnoff D, **Krackhardt A**, Weide B, Haferkamp S, Kiecker F, Izar B, Garraway L, Regev A, Flaherty K, Paschen A, Van Allen EM, Schadendorf D: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma; Nat Med 2019; https://www.nature.com/articles/s41591-019-0654-5

7. Faist B, Schlott F, Stemberger C, Dennehy KM, **Krackhardt A**, Verbeek M, Grigoleit GU, Schiemann M, Hoffmann D, Dick A, Martin K, Hildebrandt M, Busch DH, Neuenhahn M: Targeted in-vitro-stimulation reveals highly proliferative multi-virus-specific human central memory T cells as candidates for prophylactiv T cell therapy; PloS One 2019; 14(9):e0223258. doi: 10.1371/journal.pone.0223258. eCollection 2019.

8. Terheyden P, **Krackhardt A**, Eigentler T: Systemtherapie des Melanoms; Deutsches Ärzteblatt 2019; 116: 497-504.

9. Audehm S, Glaser M, Pecoraro M, Bräunlein E, Mall S, Klar R, Effenberger M, Albers J, Bianchi HO, Peper J, Yusufi N, Busch DH, Stevanovic S, Mann M, Antes I, **Krackhardt AM**: Key features relevant to select antigens and TCR from the MHC mismatched repertoire to treat cancer; Front Immunol 2019; 10: 1485; doi: 10.3389/fimmu.2019.01485

10. Albers J, Ammon T, Gosmann D, Audehm A, Thoene S, Winter C, Secci R, Wolf A, Stelzl A, Steiger K, Ruland J, Bassermann F, Kupatt C, Anton M, and **Angela M Krackhardt**: Gene editing enables T cell engineering to redirect antigen specificity for potent tumor rejection; Life Science Alliance 2019, doi: 10.26508/lsa.201900367.

11. Melzer M, Zeitlinger L, Mall S, Steiger K, Schmid R, Ebert O, **Krackhardt A**, and Altomonte J: Enhanced safety and efficacy of oncolytic vesicular stomatitis virus therapy by combination with T cell receptor transgenic T cells as carriers; Molecular Therapy: Oncolytics 2018, doi: 10.1016/j.omto.2018.12.001. eCollection 2019 Mar 29

12. Mayer KE, Mall S, Yusufi N, Gosmann D, Steiger K, Russelli L, Bianchi H, Audehm S, Wagner R, Bräunlein E, Stelzl A, Bassermann F, Weichert W, Weber W, Schwaiger M, D`Alessandria C, **Krackhardt AM**: T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target; Theranostics 2018; 8: 6070-6087.

13. Kobold S, **Krackhardt A**, Schlösser H, Wolf D: Immuno-Oncology: A brief overview; Dtsch Med Wochenschr 2018; 43:1006-1013

14. Spoerl S, Wäscher D, Nagel S, Peschel C, Verbeek M, Götze K, **Krackhardt AM**: Evaluation of the new continuous mononuclear cell collection protocol versus an older version in two different apheresis machines; Transfusion 2018, 58(7):1772-1780.

15. **Krackhardt AM**, Anliker B, Hildebrandt M, Bachmann M, Eichmüller SB, Nettelbeck DM, Renner M, Uharek L, Willimsky G, Schmitt M, Wels W, Schüssler-Lenz M: Clinical translation and regulatory aspects of CAR/TCR_based adoptive cellular therapies – the German Cancer Consortium Approach; Cancer Immunol Immunother 2018, 67:513-523.

16. Bräunlein E, **Krackhardt AM**: Identification and characterization of neoantigens as well as respective immune responses in cancer patients; Frontiers Immunology 2017; https://doi.org/10.3389/fimmu.2017.01702.

17. Audehm S, **Krackhardt AM**: Adoptive cellular immunotherapy in allogeneic stem cell transplantation; Oncol Res Treat 2017; 40: 691-696

18. Bailey DL, Pichler BJ, Gückel B, Antoch G, Barthel H, Bhujwalla Z, Biskup S, Biswal S, Bitzer M, Boellaard R, Braren RF, Brendle C, Brindle K, Chiti A, la Fougère C, Gillies R,

Goh V, Goyen M, Hacker M, Heukamp L, Knudsen GM, **Krackhardt AM**, Law I, Morris JC, Nikolaou K, Nuyts J, Ordonez AA, Pantel K, Quick HH, Riklund K, Sabri O, Sattler B, Troost EGC, Zaiss M, Zender L and T. Beyer: Combined PET/MRI: *Global Warming*; Summary Report of the 6th International Workshop on PET/MRI; March 27-29, 2017; Tübingen, Germany; MIB 2017; Mol Imaging Biol 2017; doi: 10.1007/s11307-017-1123-5.

19. **Krackhardt AM**, Heinrich B: Progress in Immunotherapy; MMW Fortschr Med. 2017 Aug;159(14):48-53. doi: 10.1007/s15006-017-9949-y. Review. German. No abstract available.

20. Bräunlein E., **Krackhardt AM**: Tools to define the melanoma-associated immunopeptidome; Immunology 2017; doi: 10.1111/imm.12803

21. Wisskirchen K, Metzger K, Schreiber S, Asen T, Weigand L, Dargel C, Witter K, Kieback E, Sprinzl MF, Uckert W, Schiemann M, Busch DH, **Krackhardt AM**, Protzer U: Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental anc clinical use; PloS One 2017; 8;12(8):e0182936. doi: 10.1371/journal.pone.0182936

22. Yusufi N, Mall S, Bianchi HO, Steiger K, Reder S, Klar R, Audehm S, Mustafa M, Nekolla S, Peschel C, Schwaiger M, **Krackhardt AM**, D`Alessandria C: In-depth characterization of a TCR-specific Tracer for sensitive detection of tumor-dericted transgenic T cells by Immuno-PET; Theranostics 2017; 7(9):2402-2416

23. Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, **Krackhardt AM**, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI: Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1-therapy in advanced melanoma; Eur J Cancer 2017 Apr;75:47-55. doi: 10.1016/j.ejca.2017.01.009

24. Degroote RL, Uhl PB, Amann B, **Krackhardt AM**, Ueffing M, Hauck SM, Deeg CA: Formin like 1 expression is increased on CD4+ T lymphocytes in spontaneous autoimmune uveitis; J Proteomics. 2017 Feb 10;154:102-108. doi: 10.1016/j.jprot.2016.12.015.

25. Spoerl S, Peter R, Wäscher D, Götze K, Verbeek M, Peschel C, **Krackhardt AM**: Patients`outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis; Transfusion 2017 Jan;57(1):115-121. doi: 10.1111/trf.13883.

26. Bassani-Sternberg M, Bräunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, Straub M, Weber J, Slotta-Huspenina J, Specht K, Martignoni ME, Werner A, Hein R, H Busch D, Peschel C, Rad R, Cox J, Mann M, **Krackhardt AM**: Direct identification of clinically relevant neoepitopes presneted on native human melanoma tissue by mass spectrometry; Nat Commun 2016; 7:13404. doi: 10.1038/ncomms13404

27. Mall S, Yusufi N, Wagner R, Klar R, Bianchi H, Steiger K, Straub M, Audehm S, Laitinen I, Aichler M, Peschel C, Ziegler S, Mustafa M, Schwaiger M, D`Alessandria C, **Krackhardt AM**: Immuno-PET imaging of engineered human T cells in tumors; Cancer Research 2016; 76: 4113-23.

28. Blaeschke F, Thiel U, Kirschner A, Thiede M, Schirmer D, Wohlleber D, Alba Rubío R,.

Grunewald TGP, Richter GHS, Mall S, Klar R, Riddell S, Busch DH, **Krackhardt AM**, Burdach S: Human HLA-A*02:01/CHM1$^+$ allo-restricted T Cell Receptor transgenic CD8$^+$ T cells specifically kill Ewing Sarcoma cells *in vitro* and in a preclinical Mouse Model; Oncotarget: 7: 43267-43280.

29. Spoerl S, Peter R, **Krackhardt AM**: Cryopreservation in closed bag systems as an alternative to clean roon for preparation of peripheral blood stem cells; Adv Exp Med Biol. 2016;951:67-76.

30. Schirmer D, Grünewald TGP, Klar R, Schmidt O, Wohlleber D, Alba Rubío R, Uckert W, Busch SH, **Krackhardt AM**, Burdach S, Richter GHS: Transgenic antigen-specific, allogeneic HLA-A*0201-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity; Oncoimmunology; 5:e1175795.

31. Anastasov N, Höfig I, Mall S, **Krackhardt AM**, Thirion C: Optimized lentiviral transduction protocols by use of a poloxamer enhancer, spinoculation, and scFv-antibody fusion to VSV-G: Methods Mol Biol. 2016;1448:49-61. doi: 10.1007/978-1-4939-3753-0_4.

32. Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, **Krackhardt AM**, Schadendorf D, Schuler G, Dummer R, Heinzerling LM: Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy; Eur J Cancer. 2016, S0959-8049(16)00151-9. doi: 10.1016/j.ejca.2016.02.025.

33. Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, **Krackhardt AM**, Schadendorf D, Schuler G, Dummer R, Heinzerling LM: Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy; Eur J Cancer, 2016, pii: S0959-8049(16)00150-7. doi: 10.1016/j.ejca.2016.02.024.

34. Hoffmann T, **Krackhardt AM**, Antes I: Quantitative Analysis of the association angle between T-cell receptor Vα/Vβ domains reveals important features for epitope recognition. PLoS Comput Biol. 2015, 17;11(7):e1004244.

35. Spoerl S, Peter R, Waescher D, Verbeek M, Menzel H, Peschel C, **Krackhardt AM**: Long-term experiences in cryopreservation of mobilized peripheral blood stem cells using a closed bag system - a technology with potential for broader application; Transfusion 2015, Jul 14. doi: 10.1111/trf.13206.

36. Dargel C, Bassani-Sternberg M, Hasreiter J, Zani F, Bockmann JH, Thiele F, Bohne F, Wisskirchen K, Wilde S, Sprinzl MF, Schendel DJ, **Krackhardt AM**, Uckert W, Wohlleber D, Schiemann M, Stemmer K, Heikenwälder M, Busch DH, Richter G, Mann M, Protzer U: T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice. Gastroenterology 2015, 149: 1042-1052.

37. Weber JS, D`Angelo SP, Minor D, Hodi S, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD, Linette G, Thomas L, Lorigan P, Grossmann K, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ,

Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J: Nivolumab compared with chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 therapy; The Lancet Oncology 2015, 16: 375-384.

38. Klar R, Schober S, Rami M, Mall S, Merl J, Hauck SM, Ueffing M, Admon A, Slotta-Huspenina J, Stevanovic S, Oostendorp RAJ, Busch DH, Peschel C, **Krackhardt AM**: Therapeutic targeting of naturally presented myeloperoxidase derived peptide ligands in myeloid leukemia cells by TCR-transgenic T cells; Leukemia 2014, 28: 2355-2366.

39. Nauerth M, Weißbrich B, Knall R, Franz T, Dössinger G, Bet J, Paszkiewicz PJ, Pfeifer L, Bunse M, Uckert W, Holtappels R, Gillert-Marien D, Neuenhahn M, **Krackhardt A**, Reddehase MJ, Riddell SR, Busch DH: TCR-ligand k_{off} rate correlates with the protective capacity of antigen-specific CD8$^+$ T cells for adoptive transfer; Sci Trans Med 2013; 192: 192ra87.

40. Han Y, Yu G, Sarioglu H, Caballero-Martinez A, Schlott F, Ueffing M, Haase H, Peschel C and **Krackhardt AM**: Proteomic investigation of the interactome of FMNL1 in hematopoietic cells unveils a role in calcium-dependent membrane plasticity. J Proteomics 2013; 78:72-82.

41. Weigand LU, Liang X, Schmied S, Mall S, Klar R, Stötzer OJ, Salat C, Götze K, Mautner J, Peschel C, **Krackhardt AM**: Isolation of human MHC class II-restricted TCR from the autologous T cell repertoire with potent anti-leukemic reactivity. Immunology 2012; 137: 226-238.

42. Höfig I, Atkinson MJ, Mall S, **Krackhardt AM**, Thirio C and Anastasov N (2012) Lentiviral transduction of T-cell lineage is enhanced by poloxamer synperonic F108. J Gene Med. 2012; 14:540-560.

43. Liang X, Weigand LU, Schuster IG, Eppinger E, van der Griendt JC, Schub A, Leisegang M, Sommermeyer D, Anderl F, Han Y, Ellwart J, Moosmann A, Busch DH, Uckert W, Peschel C, **Krackhardt AM**: A single T cell receptor (TCR) -chain with dominant peptide recognition in the allo-restricted HER2/neu-specific T cell repertoire; J. Immunol 2010; 184: 1617-1629.

44. Han Y, Eppinger E, Schuster IG, Weigand LU, Liang X, Kremmer E, Peschel C, **Krackhardt AM**: Formin-like 1 (FMNL1) is regulated by N-terminal myristoylation and induces polarized membrane blebbing; J Biol Chem 2009; 284, 33409-33417.

45. Schuster IG, Busch DH, Eppinger E, Kremmer E, Milosevic S, Hennard C, Kuttler C, Ellwart JW, Frankenberger B, Nößner E, Salat C, Bogner C, Borkhardt A, Kolb HJ, and **Krackhardt AM**: Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematological and other malignancies; Blood 2007; 110 :2931-2939.

46. **Krackhardt AM**, Witzens M, Harig S, Hodi S, Zauls J, Barrett P, Gribben JG: Identification of tumor associated antigens in chronic lymphocytic leukemia by SEREX; Blood 2002; 100: 2123-2131.

47. **Krackhardt AM**, Harig S, Witzens M, Broderick R, Barrett P, Gribben JG: T cell responses against chronic lymphocytic leukemia cells; implications for immunotherapy; Blood 2002; 100: 167-173.

48. Harig S, Witzens M, **Krackhardt AM**, Trojan A, Barrett P, Broderick R, Zauls J, Gribben JG: Induction of cytotoxic T cell responses against immunoglobulin derived peptides modified at HLA-A2 binding residues; Blood 2001; 98: 2999-3005.

49. Trojan A, Witzens M, Schultze JL, Vonderheide RH, Harig S, **Krackhardt A**, Stahel RA, Gribben JG: Generation of cytotoxic T lymphocytes against native and altered peptides og human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule; Cancer Res 2001; 61: 4761-4765.

50. **Krackhardt A**, Schwartz S, Thiel E: Targeting Folates by Carboxypeptidase G: Potential applications in anticancer therapy; Onkologie 2000; 23: 538-543.

51. **Krackhardt AM**, Gribben JG. Stem cell transplantation for indolent lymphoma; Curr Opin Hematol 1999; 6: 388-393.

52. **Krackhardt A**, Schwartz S, Korfel A, Thiel E: Carboxypeptidase-G2 rescue in a 79 year-old patient with cranial lymphoma after high-dose methotrexate induced acute renal failure; Leuk Lymphoma 1999; 35: 631-635.

53. **Krackhardt A**, Maurer J, Thiel E, Notter M. Activation of autologous lymphocytes of patients with chronic myelogenous leukemia in chronic phase with cytokines and CD3 monoclonal antibody results in BCR/ABL-negative blood leukocyte cultures as determined by RT-PCR; Exp Hematol 1998; 26: 1265-1270.